Updated real-world data shows Giotrif®/Gilotrif® (afatinib) followed by osimertinib provided a median overall survival of up to almost four years in patients with EGFR Del19 and T790M mutation-positive NSCLC

World News: . []

Boehringer Ingelheim today announced LINK  interim analysis LINK  from the GioTag study showing that initiating LINK  with afatinib followed by osimertinib LINK  an overall survival OS of LINK  four years 457 months in patients wi th Del1...

More news and information about Boehringer Ingelheim

Published By:

Business Wire: 10:36 GMT Friday 2nd August 2019

Published: .

Search for other references to "updated" on SPi News


Previous StoryNext Story

SPi News is published by Sector Publishing Intelligence Ltd.
© Sector Publishing Intelligence Ltd 2019. [Admin Only]
Sector Publishing Intelligence Ltd.
Agriculture House, Acland Road, DORCHESTER, Dorset DT1 1EF United Kingdom
Registered in England and Wales number 07519380.
Privacy Policy | Terms and Conditions | Contact Us